Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Ночной контроль уровня глюкозы с помощью искусственной поджелудочной железы в диабетическом лагере
2013-02-27
SCID: 54.1/42k4wbve
Discuss with AI
artificial pancreasnocturnal glucose controlnocturnal hypoglycemiasensor-augmented insulin pumptype 1 diabetes
Figures from the paper
Abstract (AI)
BACKGROUND: Recent studies have shown that an artificial-pancreas system can improve glucose control and reduce nocturnal hypoglycemia. However, it is not known whether such results can be replicated in settings outside the hospital. METHODS: In this multicenter, multinational, randomized, crossover trial, we assessed the short-term safety and efficacy of an artificial pancreas system for control of nocturnal glucose levels in patients (10 to 18 years of age) with type 1 diabetes at a diabetes camp. In two consecutive overnight sessions, we randomly assigned 56 patients to receive treatment with an artificial pancreas on the first night and a sensor-augmented insulin pump (control) on the second night or to the reverse order of therapies on the first and second nights. Thus, all the patients received each treatment in a randomly assigned order. The primary end points were the number of hypoglycemic events (defined as a sensor glucose value of <63 mg per deciliter [3.5 mmol per liter] for at least 10 consecutive minutes), the time spent with glucose levels below 60 mg per deciliter (3.3 mmol per liter), and the mean overnight glucose level for individual patients. RESULTS: On nights when the artificial pancreas was used, versus nights when the sensor-augmented insulin pump was used, there were significantly fewer episodes of nighttime glucose levels below 63 mg per deciliter (7 vs. 22) and significantly shorter periods when glucose levels were below 60 mg per deciliter (P=0.003 and P=0.02, respectively, after adjustment for multiplicity). Median values for the individual mean overnight glucose levels were 126.4 mg per deciliter (interquartile range, 115.7 to 139.1 [7.0 mmol per liter; interquartile range, 6.4 to 7.7]) with the artificial pancreas and 140.4 mg per deciliter (interquartile range, 105.7 to 167.4 [7.8 mmol per liter; interquartile range, 5.9 to 9.3]) with the sensor-augmented pump. No serious adverse events were reported. CONCLUSIONS: Patients at a diabetes camp who were treated with an artificial-pancreas system had less nocturnal hypoglycemia and tighter glucose control than when they were treated with a sensor-augmented insulin pump. (Funded by Sanofi and others; ClinicalTrials.gov number, NCT01238406.).
Key Findings
1
In a randomized crossover trial of 56 adolescents at a diabetes camp, an artificial pancreas was compared with a sensor-augmented insulin pump overnight.
2
Median individual mean overnight glucose was lower with the artificial pancreas than the control pump: 126.4 versus 140.4 mg/dL.
3
No serious adverse events were reported, supporting short-term safety in this nonhospital setting.
4
The artificial pancreas reduced nighttime glucose episodes below 63 mg/dL from 22 to 7 compared with the sensor-augmented pump.
5
The artificial pancreas significantly shortened the time spent below 60 mg/dL, with multiplicity-adjusted P=0.02.
Research Object
Artificial-pancreas system used for nocturnal glucose management in 10- to 18-year-old patients with type 1 diabetes at a diabetes camp
Research Subject
Short-term safety and efficacy for reducing nocturnal hypoglycemia and controlling overnight glucose levels compared with a sensor-augmented insulin pump
Publication Details
Publication Date
2013-02-27
Journal
New England Journal of Medicine
Publisher
Massachusetts Medical Society
ISSN
0028-4793
Cited by
454
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Cited by8
Artificial Intelligence for Diabetes Management and Decision Support: Literature Review2018
Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes2017
Closed-Loop Insulin Delivery Systems: Past, Present, and Future Directions2022
Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis2013
Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes2015
Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial2018
The Artificial Pancreas: Is it Important to Understand How the β Cell Controls Blood Glucose?2013
An Artificial Pancreas for Automated Blood Glucose Control in Patients With Type 1 Diabetes2015